For instance, the administration of a siRNA molecule modified to increase its in vivo delivery and stability, induces a delay in tumor growth, accompanied by an increase in the release of TNFα and IFNγ pro-inflammatory cytokines in a xenograft model of breast cancer but has never been used in the clinic (94). Here, TNF is linked to neoplasm.